IRD — Opus Genetics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1228627 ·
Last close
$3.71
Market Cap
$306.32M
52W High
$5.40
52W Low
$2.82
ADV30
1,113,567
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,157,000 | — | -14,364,000 | -65,535,000 | 66,787,000 | 59,959,000 | 112,623,000 |
| Dec 2025 | 3,865,000 | — | -11,453,000 | -16,523,000 | 50,243,000 | 45,091,000 | 34,895,000 |
| Sep 2025 | 3,079,000 | — | -8,311,000 | -17,454,000 | 36,122,000 | 30,815,000 | 30,155,000 |
| Jun 2025 | 2,882,000 | — | -8,906,000 | -7,420,000 | 38,665,000 | 32,429,000 | 21,192,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,986,000
Investing CF
$0
Financing CF
$57,153,000
CapEx
—
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.36
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-254,124,000
Inventory
—
Receivables
$2,715,000
ST Investments
$0
EBIT TTM
$-106,301,000
Pretax Income TTM
$-106,932,000
Interest Exp TTM
$3,489,000
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$11,983,000
EBITDA
$-42,981,000
Free Cash Flow
$-39,270,624
Enterprise Value
$267,952,448
Total Cash
$59,959,000
Total Debt
$1,198,000
Shares Out
82,565,835
Trailing EPS
$-1.31
Book Value
$-0.64
ROE
-7594.6%
ROA
-46.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,196,000 | -38,599,000 | -49,591,000 | 50,243,000 | 34,895,000 | — | -35,253,000 |
| Dec 2024 | 10,992,000 | -34,074,000 | -57,532,000 | 36,862,000 | 30,138,000 | — | -25,576,000 |
| Dec 2023 | 19,049,000 | -10,563,000 | -9,986,000 | 53,948,000 | 4,042,000 | — | -1,112,000 |
| Dec 2022 | 39,850,000 | 18,226,000 | 17,888,000 | 48,992,000 | 2,753,000 | — | 14,314,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | $306.69M | $5.10 | — |
| ORGO | Organogenesis Holdings Inc. | $304.96M | $2.37 | — |
| LYEL | Lyell Immunopharma, Inc. | $301.94M | $12.94 | — |
| AMRN | AMARIN CORP PLC\UK | $299.02M | $14.26 | — |
| PRLD | Prelude Therapeutics Inc | $298.62M | $4.60 | — |
News headlines (Yahoo Finance, 1h cache)
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
2026-07-09 11:00 · Yahoo
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
2026-07-06 11:00 · Yahoo
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
2026-07-05 22:08 · Yahoo
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
2026-06-26 13:15 · Yahoo
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
2026-06-16 20:05 · Yahoo
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target
2026-06-10 18:22 · Yahoo
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
2026-06-02 11:00 · Yahoo
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-28 20:01 · Yahoo
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
2026-05-26 02:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.